Potential of using structured data from clinical trials and routine for AI and radiomics research

Dr. Nils Grosse Hokamp shares his experience of using mint Lesion™ at the University Hospital Cologne in this brief interview. He talks about how they have expanded their usage of mint Lesion™ over the years, how it has changed their clinical studies, and his view on the potential of structured data for research.

Click here or on the image above to watch the full video on YouTube.

Related Resources

Related Resources

RECIST measurements of a patient with uveal melanoma and hepatic metastases

University Hospital Tuebingen: Study compares the Efficacy of SIRT and CS-PHP in Uveal Melanoma with Hepatic Metastasis

A study[1] conducted by researchers at University Hospital Tuebingen retrospectively compared the efficacy of two liver-targeted therapies,…

Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…

A picture of a person looking at a brain scan and the interface of mint Lesion™  on a computer

Advancing Neuro-Oncology Assessments: Mint Medical to Integrate Newly Published RANO 2.0 Criteria into mint Lesion™

Glioblastomas and other gliomas are the most common malignant primary brain tumor types, yet few effective therapies are available. Clinical research…